127 related articles for article (PubMed ID: 6083673)
1. [Tissue plasminogen activator activity in early prostatic cancer and in bone metastases of prostatic cancer].
Pflüger H; Kirchheimer J; Ritschl P; Köller A; Hienert G; Binder BR
Wien Klin Wochenschr; 1984 Sep; 96(17):658-61. PubMed ID: 6083673
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Camiolo SM; Markus G; Englander LS; Siuta MR; Hobika GH; Kohga S
Cancer Res; 1984 Jan; 44(1):311-8. PubMed ID: 6197164
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
Festuccia C; Vincentini C; di Pasquale AB; Aceto G; Zazzeroni F; Miano L; Bologna M
Oncol Res; 1995; 7(3-4):131-8. PubMed ID: 8555646
[TBL] [Abstract][Full Text] [Related]
5. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator content of neoplastic and benign human prostate tissues; fibrin augmentation of an activator activity.
Camiolo SM; Markus G; Evers JL; Hobika GH; DePasquale JL; Beckley S; Grimaldi JP
Int J Cancer; 1981 Feb; 27(2):191-8. PubMed ID: 6169657
[TBL] [Abstract][Full Text] [Related]
7. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
[TBL] [Abstract][Full Text] [Related]
8. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M
Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195
[TBL] [Abstract][Full Text] [Related]
9. [Characteristics of human plasminogen activator and of a fraction of fibrinolytically active plasma enriched with this enzyme].
Plastonova TK; Petrenko OA
Vopr Med Khim; 1979; 25(3):302-7. PubMed ID: 156462
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.
Markus G; Camiolo SM; Kohga S; Madeja JM; Mittelman A
Cancer Res; 1983 Nov; 43(11):5517-25. PubMed ID: 6193874
[TBL] [Abstract][Full Text] [Related]
11. The fibrinolytic system in experimental prostate tumor.
Al-Mondhiry H; Drago J; Bartholomew MJ
Thromb Haemost; 1986 Oct; 56(2):133-6. PubMed ID: 3810552
[TBL] [Abstract][Full Text] [Related]
12. Tissue plasminogen activator activity in prostatic cancer.
Köller A; Kirchheimer J; Pflüger H; Binder BR
Eur Urol; 1984; 10(6):389-94. PubMed ID: 6085049
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
14. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Moritz TE; Rousseau SM; Stump DC
Cancer; 1991 Mar; 67(5):1377-83. PubMed ID: 1703919
[TBL] [Abstract][Full Text] [Related]
15. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Björlin G; Ljungnér H; Wennerberg J; Astedt B
Acta Otolaryngol; 1987; 104(5-6):568-72. PubMed ID: 3434279
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
20. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
